Premium
Successful treatment of myelodysplastic syndrome and chronic hepatitis C using combined peginterferon‐α‐2b and ribavirin therapy
Author(s) -
Maruyama Shigeo,
Koda Masahiko,
Oi Shinnji,
Murawaki Yoshikazu
Publication year - 2014
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12274
Subject(s) - pancytopenia , ribavirin , medicine , cytopenia , gastroenterology , myelodysplastic syndromes , combination therapy , hepatitis c virus , interferon , hepatitis c , bone marrow , immunology , virus
We report a patient with myelodysplastic syndrome ( MDS ) and hepatitis C virus ( HCV ) infection who was successfully treated with a combination of peginterferon and ribavirin therapy. A 65‐year‐old man was referred to our hospital for treatment of chronic hepatitis C and close examination of pancytopenia. MDS of “refractory cytopenia with multilineage dysplasia” was diagnosed on the basis of bone marrow findings. Although the patient was not a good candidate for interferon ( IFN ) therapy because of his pancytopenia, we decided to proceed with IFN therapy for the following reasons: his elevated transaminases could not be controlled; he had a high possibility of recovery from chronic hepatitis C in consideration of his HCV genotype 2a and relatively low RNA titer; and his pancytopenia was expected to worsen in the future. After combination peginterferon/ribavirin therapy, the patient achieved sustained viral response, and the bone marrow findings showed neutrophils with normal granulation and megakaryocytes with normal morphological features. Additionally, the normal 46, XY karyotype converted from 45, X 0 which was found before IFN therapy. This suggested that the patient's MDS was completely resolved.